Cargando…
Combination chemotherapy with or without s.c. IL-2 and IFN-α: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)
The purpose of this randomized trial was to evaluate the efficacy of combination chemoimmunotherapy compared with chemotherapy alone. A total of 124 patients were randomized to receive intravenous cisplatin (35 mg m(−2), days 1–3), carmustine (150 mg m(−2), day 1, cycles 1 and 3 only), dacarbacine (...
Autores principales: | Atzpodien, J, Neuber, K, Kamanabrou, D, Fluck, M, Bröcker, E B, Neumann, C, Rünger, T M, Schuler, G, von den Driesch, P, Müller, I, Paul, E, Patzelt, T, Reitz, M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375173/ https://www.ncbi.nlm.nih.gov/pubmed/11870502 http://dx.doi.org/10.1038/sj.bjc.6600043 |
Ejemplares similares
-
Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients
por: Atzpodien, J, et al.
Publicado: (2007) -
Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
por: Atzpodien, J, et al.
Publicado: (2005) -
Interleukin-2/interferon-α2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
por: Atzpodien, J, et al.
Publicado: (2006) -
IL-2 in combination with IFN-αand 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial
por: Atzpodien, J, et al.
Publicado: (2001) -
Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1994)